Navigation Links
Phlo Reports Sharp Revenue Increase
Date:2/21/2008

JACKSONVILLE, Fla., Feb. 21 /PRNewswire-FirstCall/ -- Phlo Corporation (Pink Sheets: PHLC) (the "Company") reported revenue during the three and nine-month periods ended December 31, 2007 of $190,072 and $320,256, respectively, as compared with revenue during the three and nine-month periods ended December 31, 2006 of $3,100 and $4,723, respectively. This represents increases in revenue of $186,972 and $315,533 for the three and nine months ended December 31, 2007, respectively, as compared with the comparable periods ended December 31, 2006. Further, revenue significantly increased from $116,560 during the three months ended September 30, 2007 to $190,072 during the three months ended December 31, 2007. The Company's gross profit margin for the nine-month period ended December 31, 2007 was 49%. The report was made on the Company's Form 10-QSB which was filed with the Securities and Exchange Commission last week and which provides additional detail related to the Company's operating results for the periods covered.

The Company noted that this significant increase in revenue occurred during, typically, one of the worst quarters of the beverage year for sales because of cold weather and holidays. In addition, this revenue increase occurred in spite of the Company's transition from 17-ounce packaging to new 20-ounce bottles for its AQISS(TM) vitality beverage product. This transition, in effect, kept AQISS(TM) out of the market for a substantial period during the quarter ended December 31, 2007.

The Company incurred cost of sales during the three and nine-month periods ended December 31, 2007 of $132,149 and $164,671, respectively, as compared with cost of sales during the comparative three and nine-month periods of 2006 of $3,045 and $3,213 respectively.

AQISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell- repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.


'/>"/>
SOURCE Phlo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice
2. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
3. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Washington, USA (PRWEB) , ... December 02, 2016 ... ... role of innovative U.S.-owned and -operated small businesses in federally funded research and ... SPIE, the international society for optics and photonics . , As part of ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma Research ... the MMRF CoMMpass Study SM —the largest and most ... medicine in multiple myeloma—will be presented at the 58 ... & Exposition in San Diego ... optimize treatment strategies, as well as identify pathways and ...
Breaking Biology Technology:
(Date:11/21/2016)... 2016   Neurotechnology , a provider of ... announced that the MegaMatcher On Card fingerprint matching ... the NIST Minutiae Interoperability Exchange (MINEX) III ... steps of the evaluation protocol. ... of fingerprint templates used to establish compliance of ...
(Date:11/17/2016)... Nov. 17, 2016 Global Market Watch: ... (Disease-Based Banks, Population-Based Banks and Academics) market is to witness ... Private Biobanks shows the highest Compounded Annual Growth Rate (CAGR) ... region during the analysis period 2014-2020. North America ... 9.95% followed by Europe at 9.56% ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):